Literature DB >> 16837245

Human African trypanosomiasis: connecting parasite and host genetics.

André Garcia1, David Courtin, Philippe Solano, Mathurin Koffi, Vincent Jamonneau.   

Abstract

In West and Central Africa, the protozoan parasite Trypanosoma brucei (T. b.) gambiense causes a chronic form of Human African trypanosomiasis (HAT) that might last several years, whereas T. b. rhodesiense refers to an acute form in East Africa that lasts weeks to months. Without treatment, both forms can cause death. Diagnosis relies on detecting parasites in blood, lymph or cerebrospinal fluid. HAT was no longer considered a public health problem in the 1960s, but it returned to alarming levels in the 1990s. After intensifying case detection and treatment, WHO recently declared the situation is under control. However, research based on host and trypanosome interactions should be encouraged to help develop innovative tools for HAT diagnosis and treatment to prevent re-emergence.

Entities:  

Mesh:

Year:  2006        PMID: 16837245     DOI: 10.1016/j.pt.2006.06.011

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  13 in total

Review 1.  Tsetse flies: genetics, evolution, and role as vectors.

Authors:  E S Krafsur
Journal:  Infect Genet Evol       Date:  2008-10-17       Impact factor: 3.342

2.  Population genetics of Trypanosoma brucei gambiense, the agent of sleeping sickness in Western Africa.

Authors:  Mathurin Koffi; Thierry De Meeûs; Bruno Bucheton; Philippe Solano; Mamadou Camara; Dramane Kaba; Gérard Cuny; Francisco J Ayala; Vincent Jamonneau
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

Review 3.  Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections.

Authors:  B Bucheton; A MacLeod; V Jamonneau
Journal:  Parasite Immunol       Date:  2011-08       Impact factor: 2.280

Review 4.  Parasite-driven pathogenesis in Trypanosoma brucei infections.

Authors:  L J Morrison
Journal:  Parasite Immunol       Date:  2011-08       Impact factor: 2.280

5.  Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.

Authors:  Deuan C Jones; Irene Hallyburton; Laste Stojanovski; Kevin D Read; Julie A Frearson; Alan H Fairlamb
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

6.  Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa.

Authors:  Vincent Jamonneau; Bruno Bucheton; Jacques Kaboré; Hamidou Ilboudo; Oumou Camara; Fabrice Courtin; Philippe Solano; Dramane Kaba; Roger Kambire; Kouakou Lingue; Mamadou Camara; Rudy Baelmans; Veerle Lejon; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21

7.  Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal.

Authors:  Vincent Jamonneau; Hamidou Ilboudo; Jacques Kaboré; Dramane Kaba; Mathurin Koffi; Philippe Solano; André Garcia; David Courtin; Claude Laveissière; Kouakou Lingue; Philippe Büscher; Bruno Bucheton
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

Review 8.  A co-evolutionary arms race: trypanosomes shaping the human genome, humans shaping the trypanosome genome.

Authors:  Paul Capewell; Anneli Cooper; Caroline Clucas; William Weir; Annette Macleod
Journal:  Parasitology       Date:  2015-02       Impact factor: 3.234

Review 9.  The natural progression of Gambiense sleeping sickness: what is the evidence?

Authors:  Francesco Checchi; João A N Filipe; Michael P Barrett; Daniel Chandramohan
Journal:  PLoS Negl Trop Dis       Date:  2008-12-23

10.  Analysis of risk factors for T. brucei rhodesiense sleeping sickness within villages in south-east Uganda.

Authors:  Thomas Zoller; Eric M Fèvre; Susan C Welburn; Martin Odiit; Paul G Coleman
Journal:  BMC Infect Dis       Date:  2008-06-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.